[A18-09] Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50
Last updated 19.03.2018
Project no.:
A18-09
Commission:
Commission awarded on 05.02.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Result of dossier assessment:
No change in the conclusion compared with the dossier assessment A17-50
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-86 | Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-50 | Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-03-16 A G-BA decision was published.